CLAIMS:

1. ~~A~~ Use of a compound of general formula **I**



(**I**)

wherein X is selected from O and NH;

Y is selected from CO and –$COCH(CH_3)CO$-;

each n and p is independently selected from 0 and 1, and q is selected from 0, 1 and 2;

each R_1, R_3, R_5, R_9, R_{11}, and R_{15} is independently selected from hydrogen, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_2-C_6 alkenyl, and substituted or unsubstituted C_2-C_6 alkynyl;

R_2 is selected from hydrogen, COR_a, $COOR_a$, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_2-C_6 alkenyl, and substituted or unsubstituted C_2-C_6 alkynyl;

each R_4, R_8, R_{10}, R_{12}, and R_{16} is independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl;

each R_7 and R_{13} is independently selected from hydrogen, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_2-C_6 alkenyl, and substituted or unsubstituted C_2-C_6 alkynyl; each R_6 and R_{14} is independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; or R_6 and R_7 and/or R_{13} and R_{14} together with the corresponding N atom and C atom to which they are attached may form a substituted or unsubstituted heterocyclic group;

R_{17} is selected from hydrogen, COR_a, $COOR_a$, $CONHR_b$, $COSR_c$, $(C{=}NR_b)OR_a$, $(C{=}NR_b)NHR_b$, $(C{=}NR_b)SR_c$, $(C{=}S)OR_a$, $(C{=}S)NHR_b$, $(C{=}S)SR_c$, SO_2R_c, SO_3R_c, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, substituted or unsubstituted C_2-C_{12} alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group, with the proviso that when n, p, and q are 0 then R_{17} is not hydrogen; and

each R_a, R_b, and R_c is independently selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, substituted or unsubstituted C_2-C_{12} alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group;

or a pharmaceutically acceptable salt or stereoisomer thereof, ~~for use in~~in the manufacture of a medicament for the treatment of an autoimmune condition.

2. ~~A compound~~The use of claim 1, wherein the autoimmune condition is caused by the activation of one or more Toll-like receptor (TLR).

3. ~~A compound~~The use of claim 1, wherein the autoimmune condition is characterised by increased signalling through at least one or more Toll-like receptor (TLR).

4. ~~A compound~~The use of claim 1, wherein the autoimmune condition is characterised by increased levels of at least one pro-inflammatory cytokines.

5. ~~A compound~~The use of any of claims 1 to 4, wherein the autoimmune condition is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), scleroderma, Sjögren's syndrome, autoimmune myocarditis, type 1 diabetes, and atherosclerosis.

6. ~~A compound~~The use of claim 5, wherein the autoimmune condition is RA.

7. ~~A compound~~The use according to any one of claims 1 to 6, wherein R_3 and R_4 are independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_3 is isopropyl and R_4 is hydrogen.

8. ~~A compound~~The use according to any one of claims 1 to 7, of general formula **II**, wherein R_3 and R_4 are methyl.

9. ~~A compound~~The use according to any preceding claim, wherein R_{11} is selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_{11} is methyl or isobutyl.

10. ~~A compound~~The use according to any preceding claim, of general formula **III** wherein R_{11} is methyl and n=1.

11. ~~A compound~~The use according to any preceding claim, wherein R_1, R_5, R_9, and R_{15} are independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_1 is selected from sec-butyl and isopropyl, R_5 is isobutyl, R_9 is p-methoxybenzyl, and R_{15} is selected from methyl and benzyl.

12. ~~A compound~~The use according to any preceding claim, wherein R_8, R_{10}, R_{12}, and R_{16} are independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_8, R_{10} and R_{12} are methyl, and R_{16} is hydrogen.

13. ~~A compound~~The use according to any preceding claim, wherein R_6 and R_{14} are independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_6 is selected from hydrogen and methyl, and R_{14} is hydrogen.

14. ~~A compound~~The use according to any preceding claim, wherein R_7 and R_{13} are independently selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl; preferably wherein R_7 is methyl and R_{13} is selected from hydrogen, methyl, isopropyl, isobutyl, and 3-amino-3-oxopropyl.

15. ~~A compound~~The use according to any of claims 1 to 12, wherein R_6 and R_7 and/or R_{13} and R_{14} together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted pyrrolidine group.

16. ~~A compound~~The use according to any preceding claim, wherein R_2 is selected from hydrogen, substituted or unsubstituted C_1-C_6 alkyl, and COR_a, and wherein R_a is a substituted or

unsubstituted C_1-C_6 alkyl; preferably wherein R_2 is hydrogen.

17. ~~A compound~~The use according to any preceding claim, wherein R_{17} is selected from hydrogen, COR_a, $COOR_a$, $CONHR_b$, $(C=S)NHR_b$, and SO_2R_c, and wherein each R_a, R_b, and R_c is independently selected from substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_2-C_6 alkenyl, substituted or unsubstituted C_2-C_6 alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group; preferably wherein R_{17} is selected from hydrogen, COObenzyl, CObenzo[b]thiophen-2-yl, SO_2(p-methylphenyl), $COCOCH_3$ and $COOC(CH_3)_3$.

18. ~~A compound~~The use according to any preceding claim, wherein X is NH.

19. ~~A compound~~The use according to any of claims 1 to 17, wherein X is O.

20. ~~A compound~~The use according to any preceding claim wherein Y is CO.

21. ~~A compound~~The use according to any of claims 1 to 19, wherein Y is –$COCH(CH_3)CO$-.

22. ~~A compound~~The use according to any one of claims 1 to 6, having the following structure:


,

,

,

,

,



,



,



, and



, or



,

or pharmaceutically acceptable salts or stereoisomers thereof.

23. ~~A compound~~The use according to any one of claims 1 to 6, wherein the compound is PLD, or pharmaceutically acceptable salts or stereoisomers thereof.

24. ~~A compound~~The use according to any one of claims 1 to 6, wherein the compound is didemninB, or pharmaceutically acceptable salts or stereoisomers thereof.

25. ~~A compound~~The use according to any one of claims 1 to 6, wherein the compound is PLD.

26. ~~A compound~~The use according to any one of claims 1 to 6, wherein the compound is Didemnin B.

~~27. A pharmaceutical composition comprising a compound as defined in any of claims 1 to 26, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment of an autoimmune condition.~~

~~28. Use of a compound as defined in to any of claims 1 to 26, or a pharmaceutically acceptable salt or stereoisomer thereof, in the manufacture of a medicament for the treatment of an autoimmune condition.~~

~~29. A method of treating an autoimmune condition, wherein the method comprises administering to an individual in need thereof, a therapeutically effective amount of a compound as defined in any of claims 1 to 26, or a pharmaceutically acceptable salt or stereoisomer thereof.~~

~~30~~27. A kit comprising the compound as defined in any of claims 1 to 26, together with instructions for treating an autoimmune condition.